Hamlet BioPharma AB (publ) (XSAT:HAMLET.B)
6.08
+0.10 (1.67%)
At close: Sep 30, 2026
Hamlet BioPharma AB Balance Sheet
Financials in millions SEK. Fiscal year is July - June.
Millions SEK. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 16.41 | 5.09 | 10.76 | 23.1 | 18.39 | 39.61 |
Cash & Short-Term Investments | 16.41 | 5.09 | 10.76 | 23.1 | 18.39 | 39.61 |
Cash Growth | -42.53% | -52.69% | -53.42% | 25.60% | -53.57% | 430.07% |
Other Receivables | 3.43 | 1.79 | 1.78 | 3.92 | 0.62 | 0.95 |
Receivables | 3.43 | 1.79 | 1.78 | 3.92 | 0.62 | 0.95 |
Prepaid Expenses | 0.32 | 0.26 | 0.21 | 0.28 | - | - |
Other Current Assets | - | -0 | - | - | - | 1.17 |
Total Current Assets | 20.16 | 7.15 | 12.76 | 27.3 | 19.01 | 41.73 |
Property, Plant & Equipment | 0.42 | 0.46 | 0.22 | 0.57 | - | - |
Other Intangible Assets | 18.01 | 20.53 | 30.61 | 40.69 | 9.48 | - |
Total Assets | 38.6 | 28.14 | 43.58 | 68.57 | 28.49 | 41.73 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 2.59 | 6.55 | 2.89 | 1.23 | 0.13 | 1.72 |
Accrued Expenses | 1.97 | 1.2 | 3.65 | 1.84 | 1.08 | 1.05 |
Current Income Taxes Payable | - | 0.1 | 0.16 | 0.18 | 0.1 | 0.03 |
Other Current Liabilities | 0.25 | 0.56 | 0.56 | 0.85 | 1.23 | 0.92 |
Total Current Liabilities | 4.82 | 8.42 | 7.27 | 4.11 | 2.55 | 3.72 |
Long-Term Debt | - | - | - | - | 5 | - |
Other Long-Term Liabilities | - | - | -0 | - | -0 | -0 |
Total Liabilities | 4.82 | 8.42 | 7.27 | 4.11 | 7.55 | 3.72 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 1.9 | 1.86 | 1.78 | 1.68 | 1.12 | 1.11 |
Additional Paid-In Capital | 316.23 | 290.65 | 251.77 | 225.36 | 140.58 | 137.23 |
Retained Earnings | -284.35 | -272.79 | -217.23 | -162.58 | - | -100.32 |
Comprehensive Income & Other | - | 0 | 0 | - | -120.76 | 0 |
Shareholders' Equity | 33.78 | 19.72 | 36.32 | 64.46 | 20.94 | 38.01 |
Total Liabilities & Equity | 38.6 | 28.14 | 43.58 | 68.57 | 28.49 | 41.73 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | - | - | - | - | 5 | - |
Net Cash (Debt) | 16.41 | 5.09 | 10.76 | 23.1 | 13.39 | 39.61 |
Net Cash Growth | -42.53% | -52.69% | -53.42% | 72.49% | -66.19% | 2589.16% |
Net Cash Per Share | - | 0.03 | 0.06 | 0.14 | 0.12 | 0.36 |
Filing Date Shares Outstanding | - | 186.18 | 177.69 | 167.76 | 112.04 | 110.53 |
Total Common Shares Outstanding | - | 186.18 | 177.69 | 167.76 | 112.04 | 110.53 |
Working Capital | 15.35 | -1.27 | 5.49 | 23.19 | 16.47 | 38.01 |
Book Value Per Share | - | 0.11 | 0.20 | 0.38 | 0.19 | 0.34 |
Tangible Book Value | 15.77 | -0.81 | 5.71 | 23.77 | 11.47 | 38.01 |
Tangible Book Value Per Share | - | -0.00 | 0.03 | 0.14 | 0.10 | 0.34 |
Machinery | - | 2.83 | 2.48 | 2.45 | 0.74 | 0.74 |